DESIGN, SYNTHESIS, AND BIOLOGICAL TRACING OF 99MTC- DPDQA AS A POTENTIAL MARKER FOR TUMOR IMAGING | ||||
| Al-Azhar Journal of Pharmaceutical Sciences | ||||
| Article 5, Volume 63, Issue 1, March 2021, Page 72-85 PDF (538.02 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ajps.2021.153562 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohamed El-Zahabi
| ||||
| Department of Pharmaceutical Medicinal Chemistry & Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt. | ||||
| Abstract | ||||
| Thalidomide is a sedative drug discovered at the end of the 50s, it showed high anticancer activity so attempts were made to synthesize thalidomide analogs that had fewer side effects than the parent compound. DPDQA showed higher anticancer activities than thalidomide. Labeling of a DPDQA with 99mTc using Na2S2O4 as reducing agent was performed. The dependence of the radiolabeling yield on the concentrations of DPDQA and reducing agent, pH of the reaction mixture, reaction time, and reaction temperature was studied. Bio-distribution studies in mice with tumor induced in the right thigh were carried out. The tumor infected thigh/contralateral thigh uptake ratio (T/NT) was evaluated. The time for the maximum accumulation of the 99mTc–DPDQA in the tumor site was evaluated after administration of the compound. | ||||
| Keywords | ||||
| Technetium-99m; Thalidomide; labeling; nuclear medicine bio-distribution; Tumor imaging | ||||
|
Statistics Article View: 253 PDF Download: 354 |
||||
